文献速递病毒性肝炎

未治疗慢性丙型肝炎患者对乙型肝炎疫苗的抗体和细胞因子应答良好:中国开放标签对照研究

Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
PubMed 文献 · J Infect Dis · 2017-01-01

该研究从社区筛查中纳入未治疗的慢性HCV感染者和按1:2匹配的健康对照,均接种3剂乙肝疫苗。两组无应答率及低、正常、高应答率均无显著差异,干扰素γ及白介素2、4、5的斑点形成细胞数也无显著差异,提示未治疗慢性HCV患者接种乙肝疫苗免疫原性和安全性良好。

要点

  • 未治疗慢性HCV患者接种3剂乙肝疫苗后抗体应答率与健康对照无显著差异。
  • 两组干扰素γ及白介素2、4、5的斑点形成细胞数均无显著差异。
  • 研究初步支持未治疗慢性HCV患者接种乙肝疫苗具有良好的免疫原性和安全性。

核心结论

  • 未治疗的慢性HCV感染者接种乙肝疫苗后,体液免疫和细胞免疫应答与健康对照相当,初步证据支持该人群接种乙肝疫苗具有良好的免疫原性和安全性。

研究设计与样本

  • 开放标签对照研究,从社区筛查中识别未治疗的慢性HCV感染者和健康对照,按社区、性别和年龄(±5岁)1:2匹配。
  • 所有参与者接种3剂乙肝疫苗,第三剂后1个月检测抗-HBs,并用酶联免疫斑点法计数干扰素γ及白介素2、4、5的斑点形成细胞。

主要发现

  • HCV组无应答、低应答、正常应答和高应答率分别为3.80%、10.13%、45.57%和40.50%,健康对照组分别为1.26%、10.13%、39.24%和49.37%(所有P > .05)。
  • 两组间干扰素γ及白介素2、4、5的斑点形成细胞数均无显著差异(所有P > .05)。

临床怎么用

  • 对于未治疗的慢性HCV感染者,可按常规程序接种乙肝疫苗以预防HBV感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis B vaccine is an effective measure to prevent hepatitis B virus infection. Whether chronic hepatitis C virus (HCV) infection decreases humoral and cell-mediated immunity responses to hepatitis B vaccination is still controversial. METHODS: Patients with chronic HCV infection who were not in treatment and healthy controls, matched at a 1:2 ratio for community, sex, and age (within 5 years), were identified from a community-based screening. All participants received 3 doses of hepatitis B vaccine. Antibody to hepatitis B surface antigen was tested 1 month after the third vaccine dose and was compared between 2 groups. Spot-forming cells (SFCs) of interferon γ and interleukin 2, 4, 5, and 6 were counted by means of enzyme-linked immunospot, and SFC counts were compared between the 2 groups. RESULTS: The rates of nonresponse and low, normal, and high response were 3.80%, 10.13%, 45.57%, and 40.50% respectively, in the HCV group, and the corresponding rates in the healthy control group were 1.26%, 10.13%, 39.24%, and 49.37% (all P > .05). There were no significant differences in SFC counts between the 2 groups for interferon γ or interleukin 2, 4, or 5 (all P > .05). CONCLUSIONS: This study provided preliminary evidence of the good immunogenicity and safety of hepatitis B vaccination among patients in China with chronic hepatitis C who are not in treatment. CLINICAL TRIALS REGISTRATION: NCT 02898922.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Liu J, Qiu S, Lu J, et al. Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China. J Infect Dis. 2017. PMID: 28859430. doi:10.1093/infdis/jix295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。